Rejecting arguments about a new lethal-injection procedure, the Florida Supreme Court refused to block the scheduled Aug. 24 execution of death row inmate Mark James Asay.
The court’s majority said Asay had not shown that the introduction of the drug etomidate into the execution process put him at risk of suffering in violation of the U.S. Constitution. Corrections officials plan to use etomidate as a substitute for a previous drug, midazolam, as the first drug in a three-step process. It would be the first time etomidate, a sedative, has been used in an execution.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
